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Balanced impacts of fitness and drug
pressure on the evolution of PfMDR1
polymorphisms in Plasmodium falciparum
Marvin Duvalsaint1†, Melissa D. Conrad1†, Stephen Tukwasibwe2, Patrick K. Tumwebaze2, Jennifer Legac1,
Roland A. Cooper3 and Philip J. Rosenthal1*

Abstract
Background: Anti-malarial drug resistance may be limited by decreased fitness in resistant parasites. Important contributors to resistance are mutations in the Plasmodium falciparum putative drug transporter PfMDR1.
Methods: Impacts on in vitro fitness of two common PfMDR1 polymorphisms, N86Y, which is associated with sensitivity to multiple drugs, and Y184F, which has no clear impact on drug sensitivity, were evaluated to study associations
between resistance mediators and parasite fitness, measured as relative growth in competitive culture experiments.
NF10 P. falciparum lines engineered to represent all PfMDR1 N86Y and Y184F haplotypes were co-cultured for 40 days,
and the genetic make-up of the cultures was characterized every 4 days by pyrosequencing. The impacts of culture
with anti-malarials on the growth of different haplotypes were also assessed. Lastly, the engineering of P. falciparum
containing another common polymorphism, PfMDR1 D1246Y, was attempted.
Results: Co-culture results were as follows. With wild type (WT) Y184 fixed (N86/Y184 vs. 86Y/Y184), parasites WT and
mutant at 86 were at equilibrium. With mutant 184 F fixed (N86/184F vs. 86Y/184F), mutants at 86 overgrew WT. With
WT N86 fixed (N86/Y184 vs. N86/184F), WT at 184 overgrew mutants. With mutant 86Y fixed (86Y/Y184 vs. 86Y/184F),
WT and mutant at 86 were at equilibrium. Parasites with the double WT were in equilibrium with the double mutant,
but 86Y/Y184 overgrew N86/184F. Overall, WT N86/mutant 184F parasites were less fit than parasites with all other
haplotypes. Parasites engineered for another mutation, PfMDR1 1246Y, were unstable in culture, with reversion to WT
over time. Thus, the N86 WT is stable when accompanied by the Y184 WT, but incurs a fitness cost when accompanied by mutant 184F. Culturing in the presence of chloroquine favored 86Y mutant parasites and in the presence of
lumefantrine favored N86 WT parasites; piperaquine had minimal impact.
Conclusions: These results are consistent with those for Ugandan field isolates, suggest reasons for varied haplotypes, and highlight the interplay between drug pressure and fitness that is guiding the evolution of resistance-mediating haplotypes in P. falciparum.
Keywords: Malaria, Plasmodium falciparum, Drug resistance, Fitness, PfMDR1
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Background
Malaria remains an enormous problem in tropical
regions despite extensive efforts to control and eliminate the disease [1]. Malaria is particularly devastating in Africa, where the vast majority of cases are due
to Plasmodium falciparum, the most virulent human
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malaria parasite [2]. With development of resistance
to older drugs, standard therapy for falciparum malaria
in Africa moved to artemisinin-based combination
therapy (ACT) early this century [3]. ACT, including
artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, artesunate-mefloquine, and
artesunate-pyronaridine, combines a potent and fastacting artemisinin derivative with a slower acting partner
drug [4]. Partner drugs play a key role in assuring the efficacy of ACT, by eliminating remaining parasites after the
short acting artemisinins are cleared, and by protecting
against emergence of artemisinin resistance. However,
resistance to artemisinins in southeast Asia [5] and varied activity of most partner drugs [6] threatens the efficacy of ACT. Interestingly, widely used partner drugs
have opposing drug sensitivity profiles, with decreased
sensitivity to amodiaquine (a close relative of chloroquine) associated with increased sensitivity to lumefantrine and mefloquine [7].
Varied sensitivities to some ACT partner drugs correlate with polymorphisms in putative drug transporters
[8]. The 76T mutation in the P. falciparum chloroquine
resistance transporter (PfCRT) is associated with resistance to chloroquine and amodiaquine [9, 10], and the
K76 wild type is associated with decreased sensitivity to
lumefantrine and mefloquine [10]. The PfCRT 76T mutation was previously widespread in Africa [11], but prevalence has decreased with replacement of chloroquine by
artemether-lumefantrine as the first-line anti-malarial.
Mutations in a second putative drug transporter, the
ATP-binding cassette protein PfMDR1, also impact on
drug sensitivity [12, 13]. In particular, PfMDR1 N86Y has
the same pattern of association as PfCRT K76T, with the
86Y mutation associated with decreased sensitivity to
chloroquine and amodiaquine [10, 14], and selected by
therapy with amodiaquine [15–17], and the N86 wild type
associated with decreased sensitivity to lumefantrine and
mefloquine [10, 14], and selected by therapy with lumefantrine [16–19]. As seen for PfCRT 76T, the prevalence
of PfMDR1 86Y has decreased markedly in many regions
in recent years [11]. Two other common PfMDR1 mutations in Africa, 184F and 1246Y, have uncertain associations with drug sensitivity, although 1246Y was selected
by therapy with artesunate-amodiaquine [15] and associated with decreases in both amodiaquine sensitivity
and fitness in vitro [20]. Increased pfmdr1 copy number
is associated with decreased sensitivity to mefloquine
and lumefantrine [21, 22], but increased copy number is
uncommonly seen in African parasites [23–25].
Changes in the prevalence of key transporter mutations with changes in drug utilization suggest a complex
interplay between mediators of drug sensitivity and parasite fitness in determining genotypes now circulating in
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Africa. However, the impacts of PfMDR1 haplotypes on
P. falciparum fitness are uncertain. In co-culture experiments, wild type parasites outgrew parasites with four
introduced PfMDR1 mutations (184F, 1034C, 1042D,
1246Y) [26] and with amplification of pfmdr1 [27]. However, these experiments did not consider the PfMDR1
86Y mutation, which appears to be the key drug sensitivity mediator for this protein in Africa. In a study in
the Gambia before the advent of ACT, the prevalence
of PfMDR1 N86 wild type parasites was greater at the
beginning of the transmission season than later in that
season, consistent with a selective advantage for the wild
type parasites when selective drug pressure (primarily from chloroquine) was limited [28]. However, in two
studies culture of polyclonal Ugandan field isolates with
mixed pfmdr1 genotypes showed, surprisingly, superior growth of the mutant 86Y allele in culture over time
[29, 30]. Based on these results, it was hypothesized that
mutant 86Y parasites are more fit than wild type due to
epistasis with other mutations in the PfMDR1 gene. To
test this hypothesis, isogenic lines engineered to contain
known African PfMDR1 haplotypes in co-culture experiments were utilized, allowing direct evaluation of the
impact of PfMDR1 mutations on parasite fitness, with fitness assessed by competitive in vitro growth.

Methods
Plasmodium falciparum culture

Plasmodium falciparum NF10 parasites with introduced
PfMDR1 N86Y and Y184F mutations [14] (generously
provided by M. Isabel Veiga and David Fidock, Columbia
University) were cultured in complete medium consisting of RPMI-1640 (Invitrogen) supplemented with 0.5%
Albumax II (GIBCO Life Technologies), 0.2% sodium
bicarbonate, 100 µM hypoxanthine, 2 mM l-glutamine,
5 ug/mL gentamycin, and 25 mM HEPES at 2% haematocrit at 37 °C in an atmosphere of 5% O
 2, 5% CO2, and
90% N2.
Growth competition experiments

Parasites were synchronized at the ring stage using 5%
(wt/vol) D-sorbitol (Sigma-Aldrich) [31] and washed
three times with RPMI medium. Infected erythrocytes
were stained with SYTO-16 (Thermo Fisher Scientific),
and counts were obtained with flow cytometry. Co-cultures (2.5 mL) were prepared by mixing two lines at equal
parasitaemia at an initial total parasitaemia of 0.5% in the
culture conditions noted above. Media was changed and
dilutions made to maintain a parasitaemia of ~ 0.5% every
2 days. For each combination studied, 2–6 independent
experiments were maintained for 32 to 40 days.
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Table 1 NF10 haplotypes studied in competitive growth experiments
Haplotype

PfMDR1 sequence
86

Drug sensitivity (IC50, nM)
184

Chloroquine

Lumefantrine

Piperaquine

NY

Wild type

Wild type

185

3.2

28.9

NF

Wild type

Mutant

205

3.2

35.1

YY

Mutant

Wild type

331

0.9

35.4

YF

Mutant

Mutant

328

0.9

40.2

The haplotypes shown indicate the N86Y and Y184F sequences. Drug sensitivities are as reported previously [14]

Co‑culture with anti‑malarials

Parasites were cultured with varied concentrations of
chloroquine (Sigma-Aldrich), lumefantrine (a gift from
the Medicines for Malaria Venture), and piperaquine
(Jinan Jiaquan International Trade Co.), both with continuous and intermittent exposure to the drugs, to identify maximum concentrations that allowed growth in
culture. Parasites were then co-cultured in the indicated
concentrations of the anti-malarials, with cycles of 2 days
with and 2 days without the drugs, and culture conditions
and maintenance of parasitaemia at ~ 0.5%, as described
above.
Genetic analysis of cultured parasites

Culture aliquots were collected and stored as dried blood
spots on Whatman 3 MM filter paper every 4 days. DNA
was extracted with Chelex 100, as previously described
[32]. The ratios of co-cultured lines was determined by
pyrosequencing of extracted DNA samples by EpigenDx
(Hopkinton, MA), following methods as previously
described [30]. In brief, biotinylated PCR products were
bound to streptavidin beads and converted to singlestranded DNA sequencing templates, and the singlestranded DNA was sequenced with previously published,
position-specific primers [30] using a pyrosequencing
PSQ96 HS system following the manufacturer’s instructions (Qiagen). Every pyrosequencing run included
negative and positive controls with known sequence; as
pyrosequencing data are provided within a sequence context, the likelihood of false reads is low. The sequences
of each sample were analysed using PSQ software, and
alleles were quantified as the percentage of each base at
sites of interest.
Statistical analysis

The ratio of the percentage of each base at sites of interest for each pyrosequenced sample was natural log-transformed and used to calculate the fitness (ω’) of the
mutant
allele
as
per
the
relationship,
 
 
ln pqtt = ln pq00 + tln(ω). The relative fitness index (ω’)
for the mutant variant in each competition assay was

determined from the slope of the least-squared regression plot of log(pt /qt) against t, where t is time measured
as asexual generations (2 days), pt is the frequency of the
wild-type variant at each generation, and qt is the frequency of the mutant variant [33]. Data from multiple
competition assays were utilized in fitting this linear relationship. Selection coefficients were then derived from ω’
as per the relationship s = ω’ – 1, such that s > 0 indicates
inferior growth of the mutant and s < 0 indicates superior
growth of the mutant compared to that of the wild type.
Statistical significance was assessed using RStudio [34]. A
one-way ANOVA test was used to determine the statistical significance of s differing from 0, and a two-way
ANOVA with Tukey’s post-hoc test to compare s in the
presence or absence of drug. P-values < 0.05 were considered significant.
CRISPR‑Cas9‑mediated editing of pfmdr1

Editing was performed based on a strategy and methods described previously [35]. Plasmids pCas9-gRNAhdhfr and pT7Pol-bsd containing gRNA8, a guide RNA
that was previously demonstrated to be effective in
editing other nucleotides in pfmdr1 [35] and is located
481 nucleotides downstream of the target, were kindly
provided by Caroline L. Ng and David Fidock, Columbia University. These express human dihydrofolate
reductase (dhfr) and blasticidin S-deaminase selectable markers, respectively. A 1.4 kb fragment of donor
template encoding mutant (1246Y) PfMDR1 was amplified from genomic DNA using 5′-GAGC TCGTAT TT
GCTGTAAGAG CTAGAT TAA-3′ (SacI restriction site
underlined) and 5′-GACGTCT TTAGCTAAT TTTAC
ATAT TTT TTATATATTCC-3′ (AatII restriction site
underlined). The Q5 Site‐Directed Mutagenesis Kit
(NEB) and primers p4358 (5′-CAAGTTGATGAGT TT
GAAG GGAGAT TC AGAA AATGC A AAATTATC-3′)
and p4359 (5′-CCAG CATAAC TACCAGTAAATATA
AAAGTAAATAAG-3′) were used to introduce silent
mutations at the Cas9 binding site to prevent Cas9
cleavage of the plasmid or the edited gene. The resulting segment was then inserted into the pT7Pol‐bsd
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plasmid using the SacI and AatII restriction sites. Synchronized ring stage NF10 parasites at 5% parasitaemia
were electroporated with 50–100 µg pCas9-gRNAhdhfr and pT7Pol bsd plasmids in 800 µL cytomix
according to previously published methods [35]. Blasticidin S HCl (2 µg/mL; Santa Cruz Biotechnology) and
WR99210 (2.5 nM; Sigma-Aldrich) were supplemented
24 h post-electroporation for 6 days, followed by culture in drug free media. By day 21–28, parasites were
seen on smears, parasite DNA was Sanger sequenced
(Eurofin Genomics), and parasites were cloned via
limiting dilution to 0.5 parasites per well in 96-well
plates for a total volume of 200 µL. Media was changed
weekly, and thick smears were prepared on day 14 and
then weekly. Wells positive for parasites were expanded
to 500 µL cultures in 24-well plates, and DNA was
extracted and sequenced using primers 1246 F (5′- ATG
ATCA CAT TATATTAAA AAATGATATGAC AAAT3′) and MDR-O2 (5′- ATGATTCGATAAATTC ATC TA
TAG C AG C AA-3′). Sequencing results were compared
to the sequence of pfmdr1 (PF3D7_0523000) for the
reference 3D7 strain.

Results
Parasites under study

Plasmodium falciparum strain NF10, the product of a
genetic cross between the Brazilian 7G8 and Ghanaian GB4 strains, was engineered previously to provide lines wild type or mutant at PfMDR1 N86Y and
Y184F, loci that have been polymorphic in African
parasites [14] (Table 1). Considering other common
polymorphisms relevant to drug resistance, NF10 parasites have wild type (based on strain 3D7) sequence at
PfMDR1 positions 1034, 1042, and 1246; have one copy
of the pfmdr1 gene; and contain the PfCRT position
72–76 CVIET haplotype and 5 other PfCRT mutations
(A220S, Q271E, N326S, I356T, and R371I), a genotype
associated with resistance to chloroquine [36]. Lines
Table 2

with all possible combinations of PfMDR1 N86Y and
Y184F were subjected to competition experiments, in
which equal quantities of two lines were co-cultured
for 40 days, and the proportion of each line was quantified by pyrosequencing every 4 days (Fig. 1). Relative growth estimates were characterized based on the
ability of a line to outgrow the co-cultured line over 40
days, and used to derive per-generation relative selection coefficients (s) for wild type alleles in each competitive growth experiment (Table 2).
Impact of N86Y on parasite fitness

With the wild type Y184 sequence fixed, parasites wild
type or mutant at position 86 were in equipoise (Fig. 1A,
Table 2). With the mutant 184 F sequence fixed, parasites mutant at position 86 overgrew wild type parasites
(Fig. 1B; Table 2). Considering lines differing at both
positions, 86Y/Y184 parasites overgrew N86/184F parasites (Fig. 1C, Table 2) and N86/Y184 and 86Y/184F parasites were in equipoise (Fig. 1D; Table 2). Taken together,
these results suggest that the N86Y polymorphism has
limited impact on parasite fitness when the 184 sequence
is wild type, but that in the setting of the 184 F mutation,
surprisingly, mutant 86Y parasites are more fit than those
wild type at position 86.
Impact of Y184F on parasite fitness

With the wild type N86 sequence fixed, parasites wild
type at position 184 overgrew those mutant at this position (Fig. 1E; Table 2). With the mutant 86Y sequence
fixed, parasites wild type or mutant at position 184 were
in equipoise (Fig. 1F, Table 2). Taken together, these
results suggest that in the setting of the N86 wild type
sequence, parasites with the Y184 wild type polymorphism are more fit than those with a mutation at this
position.

In vitro growth selection coefficients for co-cultured PfMDR1 variants

Haplotype
combination

N

PfMDR1 N86
s

NY vs. YY

5

NF vs. YF

3

− 0.02

− 0.12

− 0.09

PfMDR1 Y184
Pr(>|t|)

s

Pr(>|t|)

0.39

–

–

< 0.0001

–

–

NF vs. YY

3

NY vs. YF

4

NY vs. NF

4

–

–

0.13

< 0.0001

YY vs. YF

3

–

–

− 0.03

0.17

− 0.04

< 0.0001

0.09

0.008

0.07

− 0.04

0.06

The haplotypes shown indicate the N86Y and Y184F sequences. The per-generation selection coefficient (s) was derived from the relative fitness index (ω’) as per the
relationship s = ω’ – 1, such that s < 0 and s > 0 indicate inferior and superior growth of the wild-type allele, respectively. s was considered to differ significantly from 0
when Pr(>|t|) was ≤ 0.05. N, number of independent growth competition assays analysed
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Fig. 1 Relative fitness of parasites with varied PfMDR1 sequences. Combinations of PfMDR1 N86Y and Y184F haplotypes were co-cultured in
competitive growth experiments, beginning with equal quantities of the two lines, and relative fitness was assessed based on the prevalence of
each genotype over 40 days, with the percentage of wild type shown for the loci that differed between the two lines. Each line is designated based
on the amino acid at positions 86 and 184. Co-culture experiments demonstrated three lines in equipoise (A, D, F), overgrowth of mutant parasites
(B), overgrowth of wild-type parasites (E), and selection of wild type/mixed 86Y/Y184 parasites (C). * Indicates combinations with statistically
significant selection coefficients

Fig. 2 Transfection of PfMDR1 1246Y over time. Sequence traces for 4 independent transfections are displayed (A–D). Sequencing was conducted
3–4 weeks post-transfection and then weekly during cloning and expansion. The sequences shown are for amino acids 1244 to 1248. Nucleotides
highlighted in blue and with a vertical line represent those subject to the T to G substitution that corresponds to a tyrosine (Y, mutant) to aspartic
acid (D, wild type) substitution
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Fig. 3 Impact of anti-malarials on fitness of parasites with varied PfMDR1 sequences. With wild-type fixed at PfMDR1 184, parasites wild-type or
mutant at 86 (NY vs. YY) were co-cultured in the presence of the indicated concentrations of chloroquine (A), lumefantrine (B), or piperaquine (C)
and the prevalence of each genotype was followed over 36 days. It is seen that mutant parasites are favored under chloroquine pressure, wild type
parasites are favored under lumefantrine pressure, and that there is no clear impact on genotype prevalence under piperaquine pressure

Table 3 In vitro growth selection coefficients for PfMDR1
variants (NY vs. YY) co-cultured in the presence of anti-malarials

Table 4 Summary of selection results
Selective pressure

Selected against

Selected for

Drug exposure

s

Ps

Pd

None

NF

NY, YF, YY

No drug

− 0.02

0.20

-

Chloroquine

NY

YY

Lumefantrine

YY

NY

− 0.04

0.0006

0.67

Piperaquine

No selection

− 0.08

0.001

0.03

0.5 nM, 25% IC50

0.49

0.003

< 0.0001

1 nM, 50% IC50

0.43

0.0008

< 0.0001

0.08

0.63

Chloroquine
80 nM, 25% IC50
160 nM, 50% IC50
Lumefantrine

Piperaquine
9 nM, 25% IC50

− 0.05

Analysis was as described for Table 1. Ps, P value for comparison of s to 0. Pd, P
value for comparison of s for assays performed in the presence or absence of
anti-malarials. Ps was determined using one-way ANOVA. Pd was determined
using two-way ANOVA with Tukey’s post-hoc test

Impact of D1246Y on parasite fitness

NF10 parasites engineered to carry the PfMDR1 1246Y
mutation were previously unavailable. Engineering the
1246Y mutation into NF10 parasites with and without mutations at N86Y and Y184F was attempted using
the CRISPR Cas9 system, with 6 days of selective drugs
to maintain transfected plasmids followed by culture
in drug-free media. By day 21–28, parasites were seen
on smears and cloned by limiting dilution, and parasite
DNA was isolated and sequenced weekly. In multiple
experiments, despite successful integration, parasites
with 1246Y were not stable in culture. Consistently, the
mutant sequence was replaced by wild type over time
(Fig. 2). Presumably, despite limiting dilution these cultures contained > 1 parasite clone, allowing overgrowth
over time of more fit wild type parasites that were initially
at too low abundance to be recognized by sequencing. As
numerous other diluted cultures contained no parasites,

The haplotypes shown indicate the N86Y and Y184F sequences

but none had persistence of mutant parasites, it appears
that the 1246Y mutation incurs a substantial fitness cost,
regardless of N86Y/Y184F haplotype, when introduced in
an NF10 background.
Impacts of anti‑malarials on parasite fitness

Co-culture experiments considering different PfMDR1
86 sequences (N86/Y184 vs. 86Y/Y184 parasites) were
performed in the presence of selective concentrations (50
and 25% IC50 for chloroquine and lumefantrine and 25%
IC50 for piperaquine) of anti-malarials. During co-culture
with chloroquine, parasites with the 86Y mutation overgrew those wild type at this locus (Fig. 3; Table 3). During co-culture with lumefantrine, wild type N86 parasites
overgrew mutant parasites. During co-culture with piperaquine, mutant and wild type parasites were in equilibrium. Overall, anti-malarials modified the impacts on
fitness of the N86Y polymorphism in a manner consistent with selections seen in clinical studies (Table 4).

Discussion
The in vitro fitness of P. falciparum lines with different
PfMDR1 genetic polymorphisms that have been linked
to sensitivity to key anti-malarial drugs was compared
[12, 13]. Surprisingly, the PfMDR1 86Y mutation, which
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mediates decreased sensitivity to chloroquine and amodiaquine independent of mutations in pfcrt [10, 14], but
increased sensitivity to lumefantrine and mefloquine,
was associated with enhanced fitness compared to wild
type, but only in the presence of the 184F mutation. Likewise, the wild type Y184 sequence was favored, except in
the presence of the 86Y mutation. A third PfMDR1 mutation that has been common in parts of Africa, 1246Y, was
unstable in culture. Culture with anti-malarials stabilized
polymorphisms previously associated with decreased
sensitivity to those drugs. Taken together, these results
suggest a complex interplay between PfMDR1 mutations
and parasite fitness, consistent with the changes in antimalarial therapy and P. falciparum genotypes seen in
Africa in recent years.
Plasmodium falciparum genotypes associated with sensitivity to key ACT partner drugs have changed remarkably in Africa over the last decade. Notably, the prevalence
of two polymorphisms that are associated with decreased
sensitivity to chloroquine and amodiaquine, PfCRT 76T
and PfMDR1 86Y, has decreased dramatically [11]. These
changes have followed widespread adoption of ACT, in
particular with artemether-lumefantrine, to treat uncomplicated malaria. Thus, it is reasonable to ascribe changes
in genotypes to changes in drug pressure. However, some
common polymorphisms have unclear associations with
drug sensitivity, and so their prevalence might be better
explained by impacts on fitness. This seems most likely
for Y184F, which was not clearly associated with ex vivo
drug sensitivity [10], and which maintains an intermediate prevalence in much of Africa. This study suggests
that, in the context of heavy use of chloroquine, the
184F mutation persisted due to fitness advantages of
the YF haplotype over the NF haplotype. More recently,
with reversion to N86 wild type parasites, likely due
to decreased selective pressure from chloroquine and
increased pressure from lumefantrine, it is reasonable to
expect that the 184F mutation would decrease in prevalence, but in Uganda the prevalence of this polymorphism has remained fairly stable in recent years [37, 38].
Fitness impacts of PfMDR1 polymorphisms should be
considered in light of other polymorphisms that have also
been shown to affect drug sensitivity and/or fitness, most
notably the PfMDR1 D1246Y and PfCRT 76T mutations
[39], but also other PfCRT mutations recently identified
in southeast Asian parasites [40, 41], and mediators of
artemisinin resistance in southeast Asia [42–44]. The inability to produce parasites with a stable PfMDR1 1246Y
mutation capable of in vitro growth was highly suggestive
of diminished fitness for mutant parasites, but this finding prevented comparison of fitness using competitive
growth experiments.
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It is important to put these results in a clinical context, considering widespread treatment of malaria with
ACT (primarily artemether-lumefantrine) in Africa.
Clinical trials have shown continued excellent efficacy
for leading artemisinin-based combinations across Africa
[45–47]. However, in Uganda relative loss of efficacy of
artemether-lumefantrine compared to artesunate-amodiaquine was seen, consistent with the genotypic changes
seen in recent years [45]. These new results suggest that
the PfMDR1 86Y chloroquine/amodiaquine resistance
mutation is stabilized in the presence of specific PfMDR1
haplotypes, but that drug pressure strongly influences
selection of parasite genotypes. As noted above, with
widespread utilization of artemether-lumefantrine,
the 86Y mutation is disappearing, indicating selective
pressure in the field consistent with that seen in these
co-culture experiments, and modestly decreasing the
anti-malarial efficacy of artemether-lumefantrine [45].
This study had important limitations. Although comparison of isogenic lines differing only at introduced
loci provides assurance that the impacts of the introduced polymorphisms were compared, relative growth
in culture may not be representative of relative fitness
during human infections. The studied parasites were
the products of a cross between African and Brazilian clones; arguably consideration of African parasites
may have yielded results more relevant for drug resistance in Africa. It was not possible to study all PfMDR1
mutations commonly circulating in African parasites,
as stable parasites with the PfMDR1 1246Y mutation
could not be produced. The whole genome sequences
of transfected parasites were not compared; it is possible, though unlikely, that additional mutations that
occurred by chance during the transfection process may
have impacted on parasite fitness. Most importantly,
multiple factors impact upon parasite survival in clinical infections, including inherent parasite fitness, host
immunity, multiplicity of infection, drug pressure over
the course of infection, and host genetics. In this context, these experiments have limited ability to predict
the haplotypes that will emerge and become stable over
time, but it is of interest that these results are generally
consistent with the patterns of drug use and haplotype
prevalence in Africa. However, while it was demonstrated
that the PfMDR1 184F mutation stabilizes the 86Y mutation, these data cannot explain the persistence of 184F as
86Y has disappeared in Uganda in recent years. Deeper
understanding of responses to additional selective environments will be necessary to better understand and predict evolutionary outcomes.
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Conclusions
In summary, varied impacts on fitness of PfMDR1 polymorphisms were associated with altered drug sensitivity. Notably, the 86 N wild type that mediates decreased
sensitivity to lumefantrine had decreased fitness in the
setting of the 184 F mutation compared to the Y184 wild
type. An appreciation of the contributions of different
polymorphisms and haplotypes to parasite fitness can
help us to predict changes in parasites under the pressure
of anti-malarial drug use, and thus to best utilize available drugs to treat and control malaria.
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